{"nctId":"NCT00687882","briefTitle":"Evaluation of the Duration of Therapy for Thrombosis in Children","startDateStruct":{"date":"2008-03"},"conditions":["Venous Thrombosis"],"count":532,"armGroups":[{"label":"Intervention: A","type":"EXPERIMENTAL","interventionNames":["Other: Shortened duration (6 weeks) of anticoagulant therapy"]},{"label":"Intervention: B","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Conventional duration (3 months) of anticoagulant therapy"]},{"label":"Parallel Cohort: Persistent Occlusive Thrombosis","type":"OTHER","interventionNames":["Other: No Intervention"]},{"label":"Parallel Cohort: Persistent Antiphospholipid Antibody","type":"OTHER","interventionNames":["Other: No Intervention"]}],"interventions":[{"name":"Shortened duration (6 weeks) of anticoagulant therapy","otherNames":[]},{"name":"Conventional duration (3 months) of anticoagulant therapy","otherNames":[]},{"name":"No Intervention","otherNames":[]},{"name":"No Intervention","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Children (birth to \\<21 years of age) with radiologically-confirmed acute deep venous thrombosis in the past 30 days\n2. In the opinion of the investigator, the venous thrombosis was a provoked (i.e., non-spontaneous) event (e.g.: hospitalization; Central venous catheterization; infection; dehydration; surgery; trauma; immobility; use of estrogen-containing oral contraceptive pills; flare of autoimmune/rheumatologic condition).\n\nExclusion Criteria:\n\n1. Prior episode of VTE\n2. Malignancy that, in the opinion of the treating oncologist, is not in remission (note: remission may exist on or off anti-neoplastic therapy)\n3. Systemic lupus erythematosus\n4. Pulmonary embolism that is not accompanied by DVT or is more proximal than segmental branches of the pulmonary artery\n5. Use of, or intent to use, thrombolytic therapy\n6. Chronic anticoagulant at prophylactic dosing is being or will be administered beyond 6 months post VTE diagnosis\n7. Moderate/severe anticoagulant deficiency (defined by any one of the following):\n\n   1. protein C \\<20 IU/dL if patient is ≥3 months of age, or protein C below lower limit of detection if patient is \\<3 months of age;\n   2. antithrombin \\<30 IU/dL if patient is ≥3 months of age, or antithrombin below lower limit of detection if patient is \\<3 months of age;\n   3. protein S (free antigen or activity) \\<20 IU/dL.","healthyVolunteers":false,"sex":"ALL","maximumAge":"20 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy Outcome - Occurrence of Symptomatic Recurrent Venous Thromboembolism","description":"Occurrence of symptomatic recurrent venous thromboembolism. Primary safety endpoint is occurrence of clinically-relevant bleeding (major + clinically-relevant non-major) bleeding.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety Outcome - Occurrence of Clinically-relevant (i.e. Major Plus Clinically-relevant Non-major (CRNM)","description":"Occurrence of clinically-relevant (i.e. major plus clinically-relevant non-major (CRNM) bleeding","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Outcome 1 - Occurrence of Symptomatic Recurrent Venous Thromboembolism (VTE) or Development of Post Thrombotic Syndrome (PTS) (Composite Endpoint)","description":"Occurrence of symptomatic recurrent venous thromboembolism (VTE) or development of Post Thrombotic Syndrome (PTS) (composite endpoint)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Outcome 2 - Occurrence of Symptomatic Recurrent Venous Thromboembolism (VTE)","description":"Occurrence of symptomatic recurrent venous thromboembolism (VTE) in the intention to treat (ITT) population.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Outcome 3 - Development of Post Thrombotic Syndrome (PTS)","description":"Development of Post Thrombotic Syndrome (PTS)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":207},"commonTop":["Pyrexia","Vomiting","Upper respiratory tract infection","Nasopharyngitis","Pain in extremity"]}}}